Patents by Inventor Helen Rachel Lagiakos

Helen Rachel Lagiakos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 11911372
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 27, 2024
    Assignee: CTXT PTY LTD
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Compounds
    Publication number: 20210213004
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: July 15, 2021
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Compounds
    Publication number: 20200039945
    Abstract: A compound of formula (I), or a pharmaceutical salt thereof:
    Type: Application
    Filed: June 20, 2019
    Publication date: February 6, 2020
    Applicant: CTxT Pty Limited
    Inventors: Helen Rachel Lagiakos, Benjamin Joseph Morrow, Richard Charles Foitzik, Catherine Fae Hemley, Michelle Ang Camerino, Paul Anthony Stupple, Ylva Elisabet Bergman Bozikis, Scott Raymond Walker
  • 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
    Patent number: 9856252
    Abstract: Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from: a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are ? to one another; L1 is selected from: (i) A1—O—CH2—A2; (ii) A1—CH2—O—A2; (iii) A1—C(?O)—NH—A2; (iv) A1—CH(OH)—A2; (v) A1—CH2—NH—C(?O)—A2; (vi) A1—S—CH2—A2; (vii) A1—CH2—S—A2; (viii) A1—CH2—A2; and (ix) A1—CH(CH3)—O—A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: January 2, 2018
    Assignee: Cancer Therapeutics CRC Pty Ltd
    Inventors: Paul Anthony Stupple, Scott Raymond Walker, Jo-Anne Pinson, Helen Rachel Lagiakos, Gillian Elizabeth Lunniss, Ian Peter Holmes, Alexandra Elizabeth Stupple, Ylva Elisabet Bergman, Richard Charles Foitzik, Wilhelmus Johannes Antonius Kersten, Michelle Ang Camerino
  • 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE
    Publication number: 20160222005
    Abstract: Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from: a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are ? to one another; L1 is selected from: (i) A1—O—CH2—A2; (ii) A1—CH2—O—A2; (iii) A1—C(?O)—NH—A2; (iv) A1—CH(OH)—A2; (v) A1—CH2—NH—C(?O)—A2; (vi) A1—S—CH2—A2; (vii) A1—CH2—S—A2; (viii) A1—CH2—A2; and (ix) A1—CH(CH3)—O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 4, 2016
    Inventors: Paul Anthony Stupple, Scott Raymond Walker, Jo-Anne Pinson, Helen Rachel Lagiakos, Gillian Elizabeth Lunniss, Ian Peter Holmes, Alexandra Elizabeth Stupple, Ylva Elisabet Bergman, Richard Charles Foitzik, Wilhelmus Johannes Antonius Kersten, Michelle Ang Camerino